Clicca qui per scaricare

Ricerca e impiego degli psicofarmaci
Titolo Rivista: RIVISTA SPERIMENTALE DI FRENIATRIA 
Autori/Curatori:  Antonio Maone 
Anno di pubblicazione:  2016 Fascicolo: Lingua: Italiano 
Numero pagine:  20 P. 23-42 Dimensione file:  189 KB
DOI:  10.3280/RSF2016-002003
Il DOI è il codice a barre della proprietà intellettuale: per saperne di più:  clicca qui   qui 


Il quadro della ricerca sugli psicofarmaci appare oggi piuttosto controverso. Accanto a dati sulla loro efficacia supportati dai trial clinici e al costante incremento del loro utilizzo, infatti, sono emersi dati contraddittori da studi nel mondo reale e sulla reale entità della rilevanza clinica in confronto al placebo. Si tratta di un campo complesso in cui molte variabili entrano in gioco. Alcuni aspetti chiave possono essere comunque essere messi a fuoco, al fine di promuovere un diverso atteggiamento, più riflessivo e critico, nella pratica clinica.


Keywords: Psicofarmaci, antipsicotici, antidepressivi.

  1. [1] www.pfizer.com
  2. [2] Nestler EJ, Hyman S. Animal models of neuropsychiatric disorders. Nature Neuroscience 2010; 13: 1161-9.
  3. [3] Angell M. The Epidemic of mental illness: why? The New York Review of Books 2011; 3: 2011.
  4. [4] Leo J, Lacasse JR. The media and the chemical imbalance Theory of depression. Society 2008; 45: 35-45
  5. [5] Kandel E. The new science of mind. The New York Times; September, 6, 2013.
  6. [6] Van Os J, Kapur S. Schizophrenia. Lancet 2009; 374: 635–45.
  7. [7] Moreno JL, Gonzàles-Maeso J. Preclinical models of antipsychotic drug action. International Journal Neuropsychopharmacology 2013; 16: 2131–44.
  8. [8] Powell CM, Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biological Psychiatry 2006; 59: 1198–207.
  9. [9] Moncrieff J, Cohen D. How do psychiatric drugs work? British Medical Journal 2009; 338: 1535-7.
  10. [10] Thacker SK, Perna MK, Ward JJ, Schaefer TL, Williams MT, Kostrzewa RM, et al. The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. European Journal of Neuroscience 2006; 24: 2075–83.
  11. [11] Dorph-Petersen K-A, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005; 30: 1649–61.
  12. [12] Dreifus C. A Conversation with Nancy C. Andreasen. Using imaging to look at changes in the brain. The New York Times. Published: September 15, 2008.
  13. [13] Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes. A longitudinal study of firstepisode schizophrenia. Archives of General Psychiatry 2011; 68:128-37.
  14. [14] Ahmed M, Cannon DM, Scanlon C, Holleran L, Schmidt H, McFarland J, et al. Progressive brain atrophy and cortical thinning in schizophrenia after commencing clozapine freatment. Neuropsychopharmacology 2015; 40: 2409-17.
  15. [15] Moncrieff J, Leo J. A systematic review of the effects of antipsychotic drugs
  16. on brain volume. Psychological Medicine 2010; 20: 1-14.
  17. [16] Baldessarini RJ. A plea for integrity of the bipolar disorder concept. Bipolar Disorders. 2000; 2: 3-7.
  18. [17] Barnes TRE. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2011; 25: 567-620.
  19. [18] Andreasen NC, Carpenter WT, Kane JM, Lasser, RA Marder SR, Weinberger DR. Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry 2005; 162: 441-9.
  20. [19] Correll CU, Kishimoto T, Nielsen J, Kane J. Clinical relevance of treatments for schizophrenia. Clinical Therapeutics 2011; 33: 616–39.
  21. [20] Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013; 70: 913-20.
  22. [21] Harrow M, Jobe TH. Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophrenia Bulletin 2013; 39: 962-5.
  23. [22] McGorry P, Alvarez-Jimenez M, Killackey E. Antipsychotic medication during the critical period following remission from first-episode psychosis. Less is more. JAMA Psychiatry 2013; 70: 898-900.
  24. [23] Grace AA. Neuropharmacology. Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology 2012; 62: 1342–8.
  25. [24] Barbato A. La terapia farmacologica a lungo termine favorisce la guarigione delle psicosi? In: Maone A, D’Avanzo B, ed. Recovery. Nuovi paradigmi per la salute mentale. Milano: Raffaello Cortina Editore; 2015, p. 152-61.
  26. [25] Katschnig H. Are psychiatrists an endangered species? Observations on internal and external challenges to the profession. World Psychiatry 2010; 9: 21-28.
  27. [26] Lieberman JA, Stroup TS, Mcevoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005; 353: 1209-23.
  28. [27] Leucht S, Beitinger R, Kissling W. On the concept of remission in schizophrenia. Psychopharmacology 2007; 194: 453-61.
  29. [28] Lepping P, Sambhi RS, Whittington R, Lane S, Poole R. Clinical relevance of findings in trials of antipsychotics: systematic review. British Journal of Psychiatry 2011; 198: 341-5.
  30. [29] Karow A, Naber D, Lambert M, Moritz S. Remission as perceived by people with schizophrenia, family members and psychiatrists. European Psychiatry 2012; 27: 426-31.
  31. [30] Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: A meta-analysis of the outcome literature. American Journal of Psychiatry 1994; 151: 1409-16. [31] Warner R. Recovery from schizophrenia: psychiatry and political economy. New York: Brunner-Routledge; 2004.
  32. [32] Jääskeläinen E, Juola P, Hirvonen N, Mcgrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin 2012; 39: 1296-306.
  33. [33] Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45: 789-96.
  34. [34] Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs - an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophrenia Bulletin 2009; 35:789-97.
  35. [35] Leucht S, Davis JM. Are all antipsychotic drugs the same? British Journal of Psychiatry 2011; 199: 269-71.
  36. [36] Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 2000; 321:1371-6.
  37. [37] Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 2006; 63: 1079-87.
  38. [38] Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31–41.
  39. [39] National Institute for Clinical Excellence. Guidance on use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal no. 43. NICE 2002.
  40. [40] Hyman SE. Revitalizing psychiatric therapeutics. Neuropsychopharmacology 2014; 39: 220–9.
  41. [41] 100 Most prescribed, best-selling branded drugs through september. Medscape. Nov 03, 2014. http://www.medscape.com/viewarticle/834273#vp_1
  42. [42] Kendall T. The rise and fall of the atypical antipsychotics. British Journal of Psychiatry 2011; 199: 266-8.
  43. [43] Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA, et al. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. American Journal of Psychiatry 2005; 162: 1957-60.
  44. [44] Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L. Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychotherapy and Psychosomatics 2006; 75: 154–60.
  45. [45] Singer N, Wilson D. Medical editors push for ghostwriting crackdown. New York Times, 18 September 2009.
  46. [46] Khan A, Brown WA. Antidepressants versus placebo in major depression: an overview. World Psychiatry 2015; 14: 294–300.
  47. [47] Bernstein CA. Meta-Structure in DSM-5 process. Psychiatric News 2011. http://psychnews.psychiatryonline.org/doi/10.1176/pn.46.5.psychnews_46_5_7
  48. [48] Insel T. Director’s blog: Antidepressants: a complicated picture. December 6,a2011;http://www.nimh.nih.gov/about/director/2011/antidepressants-acomplicated-picture.shtml
  49. [49] Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005–2008. NCHS Data Brief 2011; 76 http://www.cdc.gov/nchs/products/databriefs/db76.htm
  50. [50] Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry 2006; 163: 1905-17.
  51. [51] Kirsch I. Antidepressants and the placebo effect. Zeitschrift Fur Psychologie 2014; 222:128-34.
  52. [52] Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 2008; 358: 252–60.
  53. [53] Khin NA, Chen YF, Yang Y, Yang P, Laughren TP. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. Journal of Clinical Psychiatry 2011; 72: 464–72.
  54. [54] Fountoulakis KN, Möller HJ. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. International Journal of Neuropsychopharmacology 2010; 14: 405–12.
  55. [55] Huedo-Medina TB, Johnson BT, Kirsch I. Kirsch et al.’s (2008) calculations are correct: reconsidering Fountoulakis & Möller’s re-analysis of the Kirsch data. International Journal of Neuropsychopharmacology 2012; 15: 1193-8.
  56. [56] Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC. Antidepressant drug effects and depression severity. A patient-level metaanalysis. JAMA 2010; 303: 47-53.
  57. [57] Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine 2008; 5: 45.
  58. [58] Kinon BJ, Potts AJ, Watson SB. Placebo response in clinical trials with schizophrenia patients. Current Opinion in Psychiatry 2011; 24: 107-13.
  59. [59] Read J., Bentall R. The effectiveness of electroconvulsive therapy: A literature review. Epidemiologia e Psichiatria Sociale 2010; 19: 333-47.
  60. [60] Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Placebo Effects: Biological, Clinical and Ethical Advances. Lancet 2010; 375: 686–95. [61] Peciña M, Bohnert ASB, Sikora M, Avery ET, Langenecker SA, Mickey BJ, et al. Association between placebo-activated neural systems and antidepressant responses neurochemistry of placebo effects in major depression. JAMA Psychiatry 2015; 72: 1087-94.
  61. [62] Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. British Journal of Psychiatry 2012; 200: 97-106.

Antonio Maone, in "RIVISTA SPERIMENTALE DI FRENIATRIA" 2/2016, pp. 23-42, DOI:10.3280/RSF2016-002003

   

FrancoAngeli è membro della Publishers International Linking Association associazione indipendente e no profit per facilitare l'accesso degli studiosi ai contenuti digitali nelle pubblicazioni professionali e scientifiche